{"doi":"10.1016/j.eclinm.2024.102480","title":"Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study","abstract":"Background: ABVD (doxorubicin, bleomycin, vinblastine, and dexamethasone) is a proven, curative regimen for Hodgkin lymphoma (HL). Prospective data describing HL treatment in sub-Saharan Africa are limited. We aimed to fill this knowledge gap, using data from Malawi. Methods: 15) from a single, tertiary referral centre in Malawi. We enrolled patients with pathologicially confirmed Hodgkin lymphoma between June 1, 2013, and Dec 31, 2021 with follow-up censored on May 31, 2022. Patients were treated with ABVD and concurrent antiretroviral therapy if HIV-positive and were followed up for 5 years. The primary outcome was overall survival; secondary outcomes included progression-free survival, response assessment, and adverse events. Microcosting of HL diagnosis, treatment, and follow-up was embedded. Findings: We enrolled 38 patients with a median age of 27 years (interquartile range 19-46); eleven (28%) were HIV-positive. Of 35 patients treated with ABVD, 24 (71%) had stage III/IV, nine (26%) unfavourable limited stage, and two (6%) favourable limited stage. Among HIV-infected individuals, mean CD4 count at HL diagnosis was 179 cells/uL and ten (91%) had HIV RNA < 400 copies/mL. Grade 3/4 neutropenia occurred in 24 (68%) patients and caused treatment delay in 16 (46%). Of ten deaths, seven were due to HL, two possible treatment-related toxicity, and one uncertain. 2-year overall survival was 82% (95% CI 70-96%) and 2-year progression-free survival was 64% (95% CI 50-83%). PFS appeared better for HIV-positive patients (HR 0.23 (95% CI 0.05-1.02)) after controlling for stage and performance status (p = 0.05). We estimated $2708 (2022 USD) for HL diagnosis, treatment, and follow-up in our cohort. Interpretation: Our findings suggest that treatment with ABVD is safe, efficacious, and affordable for HL in Malawi. Outcomes are worse than in high-income countries due to HL progression. Future studies are needed to understand outcome inequities and to assess efficacy of therapies for patients with relapsed or refractory HL in Malawi. Funding: National Institutes of Health, Lineberger Comprehensive Cancer Center.","journal":"EClinicalMedicine","year":2024,"id":436162,"datarank":0.4399630589875573,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.06722706151935713,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.06722706151935713,"corpus_percentile":57.42244913746422,"corpus_rank":5505,"citation_count":11,"citer_count":7,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.6766,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":964425,"name":"Evaristar Kudowa","orcid":null,"position":1,"is_corresponding":false},{"id":1244247,"name":"Dalton M. Craven","orcid":"0009-0004-1373-0173","position":2,"is_corresponding":false},{"id":823527,"name":"Luke Eastburg","orcid":"0000-0001-6123-5848","position":3,"is_corresponding":false},{"id":597065,"name":"Maria Chikasema","orcid":null,"position":4,"is_corresponding":false},{"id":597416,"name":"Edwards Kasonkanji","orcid":"0000-0002-1543-814X","position":5,"is_corresponding":false},{"id":597426,"name":"Tamiwe Tomoka","orcid":"0000-0002-5183-8714","position":6,"is_corresponding":false},{"id":1244700,"name":"Sophie Maharry Roush","orcid":null,"position":7,"is_corresponding":false},{"id":1244701,"name":"Lusayo Simwinga","orcid":null,"position":8,"is_corresponding":false},{"id":592838,"name":"Noel Mumba","orcid":null,"position":9,"is_corresponding":false},{"id":281461,"name":"Satish Gopal","orcid":"0000-0003-2314-0316","position":10,"is_corresponding":false},{"id":281459,"name":"Yuri Fedoriw","orcid":"0000-0002-2135-2908","position":11,"is_corresponding":false},{"id":281457,"name":"Matthew Painschab","orcid":"0000-0001-9175-7436","position":12,"is_corresponding":false},{"id":975438,"name":"Marriam Mponda","orcid":null,"position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T02:00:12.706156Z","pmid":"38356728","pmcid":"PMC10864874","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}